Genmab — Oktober 2023
-
Kort video...Speedsnak om rentespøgelset ...Det store rentespøgelse fylder på aktiemarkederne. Helge Larsen taler om, hvorfor det ikke har materialiseret sig noget før, hvad psykologierne er på markedet, hvordan det har ændret sig gennem tiden, og hvor det bærer henad.
https://www.proinvestor.com/boards/116364 -
“Practice-Changing Study”: Tisotumab Vedotin Boosts Survival in Metastatic Cervical Cancer https://www.obroncology.com/article/practice-changing-study-tisotumab-vedotin-boosts-survival-in-metastatic-cervical-cancer
-
“This is a practice-changing study,” said Krishnansu S. Tewari, MD, a discussant for the ESMO session and a professor and division director of gynecologic oncology at the University of California, Irvine. “It’s going to convert the accelerated approval of tisotumab vedotin in the United States to full approval, and importantly, it’s going to introduce a brand-new cervical cancer medicine to Europe.”
-
biontech had a bit more on GEN1059
DuoBody-EpCAMx4-1BB in their ESMO presentation https://investors.biontech.de/system/files-encrypted/nasdaq_kms/assets/2023/10/26/10-55-13/ESMO 2023_BNTX data_external slide deck.pdf -
-
Gasolin82: Iflg første voldgift skal jnj betale royalties indtil sidste patent udløber omkring 2030. Hvis genmab vinder appellen af den anden voldgift skal jnj også betale royalties af faspro versionen i 13 år fra første salg af faspro, som blev godkendt i 21.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind